Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07602335 · ClinicalTrials.gov registry record · Early Phase 1
Safety, Tolerability, and Pharmacokinetics of MCAM in Healthy Adult Participants
A Early Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
NCT07602335 is a Early Phase 1 study that has not yet begun recruiting, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 24 participants.
The verdict
NCT07602335, a Early Phase 1 study, has not yet begun recruiting, sponsored by The University of Texas Health Science Center at San Antonio.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to test the safety and to see if there are any side effects of the investigational drug, MCAM. The main aim is to measure blood levels of the study drug after oral administration. Researchers will compare the active study drug to a placebo to test for any differences between the two groups. Participants will be screened for up to 28 days before starting study treatment. Following the screening visit, participants will be admitted to a clinic for 4 days for treatment with either the study drug or placebo. They will attend a follow-up visit on Days 5 and 7 and participate in a follow-up phone call on Day 8. Three different doses will be tested to find the highest safe dose.
Interventions
- OTHER Placebo
- DRUG MCAM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-08-08 |
| Est. Completion | 2027-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07602335
The ClinicalTrials.gov registry entry for NCT07602335 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07602335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07602335 about?
NCT07602335 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of MCAM in Healthy Adult Participants". The goal of this clinical trial is to test the safety and to see if there are any side effects of the investigational drug, MCAM. The main aim is to measure blood levels of the study drug after oral administration. Researchers will compare the active study drug to a placebo to test for any differen...
What is the current status of trial NCT07602335?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2026-08-08. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT07602335?
The interventions under investigation include: Placebo (OTHER), MCAM (DRUG).
Who is sponsoring clinical trial NCT07602335?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.